AstraZeneca’s stock rose sharply on Tuesday after the company reported better-than-expected sales for its fourth-quarter earnings. The boost came from strong sales of several cancer drugs, including Tagrisso and Calquence, which treat lung cancer, leukemia, and lymphoma.
Tagrisso saw revenue exceed expectations at $1.9 billion, driven by uptake in all types of patients across different regions. This positive news helped push AstraZeneca’s stock price up 103% on Monday, with the company maintaining a strong position after the initial surge.
The successful performance of these cancer drugs has earned AstraZeneca an upgrade to its rating from Leerink Partners analyst Andrew Berens. With this development, investors are optimistic about the company’s future prospects in the biotech industry.
Source: https://www.investors.com/news/technology/astrazeneca-stock-astrazeneca-earnings-q4-2025